The SHIGETECVAX project brings together a multidisciplinary consortium of partners who have complementary expertise in vaccine Research and Development (R&D) - from antigen discovery, over preclinical R&D and up to the early and mid-stage clinical testing of vaccine candidates in clinical trials - management, communication and innovation. 

The coordination of the SHIGETECVAX project is assured by the Project coordinator, the European Vaccine Initiative (EVI), through EVI’s Project Management Team, the Project Steering Committee (SC) and the General Assembly (GA). 

 

To increase the chance of success towards the set objectives, i.e. the development of a safe and effective vaccine to prevent Shigella and ETEC infections, the consortium is supported by a Scientific and Ethics Advisory Committee (SEAC) that will provide scientific, technical and ethical advice and support to the consortium.